Haywood Securities says Curaleaf Holdings (Curaleaf Holdings Stock Quote, Chart, News, Analysts, Financials TSX:CURA) remains well positioned despite near-term pressure in cannabis equity markets.
In an Aug. 6 update, analyst Neal Gilmer reiterated his “Buy” rating and $17.25 target on Curaleaf. His target is based on 14 times his 2027 EBITDA estimate, discounted at 15%.
“Curaleaf reported Q2 results that were ahead of expectations,” Gilmer said. “Growth was once again driven by international markets, increasing 26% while the domestic segment grew by 7%.”
Curaleaf reported Q2 revenue of $340.1-million, up 9.5% year-over-year and above Gilmer’s $332.3-million forecast. Adjusted EBITDA was $70.1-million, representing a 20.6% margin and ahead of his $67.2-million estimate.
Adjusted gross margin improved sequentially to 50.2%, above Gilmer’s 48.5% forecast. Cash from operations was $29-million, while free cash flow was $13-million after $16-million of capital spending.
The company ended the quarter with $107.0-million of cash and $611.5-million of debt, net of unamortized discounts.
During the quarter, Curaleaf opened two retail locations in Florida and added two more after quarter-end, bringing its Florida total to 75 and its managed retail footprint to 176 locations. The company also completed the buyout of the remaining 45% interest in Four20 Pharma.
After quarter-end, Curaleaf’s Spanish subsidiary became the first company to receive approval for two cannabis medicines.
Management guided for low-single-digit sequential revenue growth in Q3, citing improved pricing in core markets while noting consumer risks from higher energy prices and potential rate increases. It also reiterated expected 2026 capital spending of about $80-million.
Gilmer said Curaleaf has growth opportunities in international markets and adult-use sales in Maryland, Connecticut and Ohio, with further optionality in states such as Pennsylvania if adult-use cannabis is launched.
The analyst raised his EBITDA forecast after the quarter, citing cost initiatives expected to support margin expansion in the second half of the year.
Gilmer expects Curaleaf to generate Adjusted EBITDA of $287.1-million on revenue of $1.37-billion in fiscal 2026, improving to Adjusted EBITDA of $332.3-million on revenue of $1.47-billion in fiscal 2027.
-30-
NowVertical Group’s (NowVertical Group Stock Quote, Chart, News, Analysts, Financials TSXV:NOW) growing artificial intelligence business and recent $15.1-million financing could… [Read More]
National Bank Financial analyst Nathan Po raised his target for Mattr Corp. (Mattr Corp. Stock Quote, Chart, News, Analysts, Financials… [Read More]
On Nov. 16, RBC Capital Markets analyst Sabahat Khan raised his target for AutoCanada (AutoCanada Stock Quote, Chart, News, Analysts,… [Read More]
iFabric’s (iFabric Corp. Stock Quote, Chart, News, Analysts, Financials TSX:IFA) stronger-than-expected third-quarter results and growing recurring sales prompted Haywood Securities… [Read More]
Metatek-Group’s (Metatek-Group Stock Quote, Chart, News, Analysts, Financials TSX:MTEK) strong sequential revenue growth and expectations for a further improvement in… [Read More]
Ascend Wellness Holdings’ (Ascend Wellness Holdings Stock Quote, Chart, News, Analysts, Financials CSE:AAWH.U) return to year-over-year revenue growth and improving… [Read More]